去螯合(转金属化):线性钆基对比剂的相关后果与安全性担忧——基于欧洲EMA、美国FDA和日本PMDA近期医疗裁决的视角
本文基于广泛聚焦的文献综述,讨论线性钆基对比剂体内去螯合(转金属化)及其安全性问题。早期警示包括两种最不稳定制剂中过量配体的使用及对实验室检查的干扰;2014年发现肾功能正常患者多次注射线性钆螯合物后precontrast T1WI齿状核高信号,推动后续研究。动物及人类长期数据发现骨、皮肤、肝内钆水平意外升高(人类数据有限),骨可能作为长期储库。欧洲已撤市线性制剂(肝胆特异性制剂用于延迟肝成像除外)。
要点
- 线性钆剂体内去螯合可致骨、皮肤、肝内钆长期沉积,骨可能为长期储库并缓慢释放。
- precontrast T1WI齿状核高信号与既往多次线性钆剂注射相关(肾功能正常患者)。
- 欧洲已撤市线性制剂,肝胆特异性制剂用于延迟肝成像除外,大环类无此担忧。
核心结论
- 线性钆基对比剂体内去螯合(转金属化)引发安全性担忧,包括骨、皮肤、肝内钆长期沉积及潜在临床后果;欧洲已撤市线性制剂(肝胆特异性制剂用于延迟肝成像除外),大环类螯合物不适用这些担忧。
研究设计与样本
- 基于广泛聚焦文献综述的论述性文章,未报告系统检索策略、纳入文献数量或证据分级。
关键影像表现/征象
- precontrast T1加权扫描上齿状核高信号与既往多次线性钆螯合物注射相关(肾功能正常患者,2014年报道)。
- 动物模型和人类长期随访发现骨、皮肤和肝内钆水平意外升高,但人类数据有限。
- 骨可能作为长期储库,线性制剂静脉注射后因骨内缓慢释放存在残余排泄期。
临床应用与阅片要点
- 作者指出可能易感人群包括儿童、绝经后女性、骨质疏松患者、接受多剂者、促炎状态者、中度肾功能不全者或未定义遗传易感者。
- 作者特别关注类似肾源性系统性纤维化症状(尤其疼痛和皮肤/关节症状)或钆掺入骨羟基磷灰石相关疾病,见于尚未定义倾向和/或辅因子的小亚组患者。
- 欧洲已撤市线性制剂,肝胆特异性制剂用于延迟肝成像的适应证除外,该适应证当前大环类钆螯合物无法满足。
局限性
- 人类长期数据有限。
- 目前仅有有限数据和小型回顾性非对照研究。
- 易感人群的倾向和/或辅因子尚未定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The issue of dechelation (transmetallation) in vivo after administration of the linear gadolinium-based contrast agents, and potential safety concerns, is considered on the basis of an extensive, focused literature review. Early indications of potential problems included the high level of excess ligand used in the formulation of 2 agents (indeed the 2 least stable thermodynamically) and interference with laboratory tests when blood was drawn from patients relatively soon after administration of these same agents. The advent of nephrogenic systemic fibrosis in the late 2000s raised additional major concerns.The correlation in 2014 of dentate nucleus hyperintensity on precontrast T1-weighted scans with multiple prior injections of linear gadolinium chelates, in patients with normal renal function, has driven subsequent research concerning dechelation of these agents in vivo. Unexpectedly high levels of gadolinium in the bone, skin, and liver have been found long term after administration, in animal models and in humans, although the latter data are limited. Bone may serve as a long-term reservoir, with a residual excretion phase for gadolinium after intravenous injection of the linear agents due to a subsequent slow release from bone. Many different patient populations could be vulnerable and potentially later develop clinical symptoms, although at this stage there are only limited data and small retrospective uncontrolled studies. Possible vulnerable populations include children, menopausal women, patients with osteoporosis (who are predisposed to fractures and often slow to heal or heal poorly), those receiving multiple doses, those with proinflammatory conditions, moderate renal dysfunction, or an undefined genetic predisposition. Of particular concern would be nephrogenic systemic fibrosis-like symptoms-including particularly pain and skin/joint symptoms, or disease related to the incorporation of gadolinium in hydroxyapatite in bone, in small subgroups of patients with a not yet defined propensity and/or cofactor. These concerns have led to withdrawal of the linear agents from the largest clinical market, Europe, with the exception of the hepatobiliary agents for delayed liver imaging, an indication that cannot be fulfilled by the current macrocyclic gadolinium chelates (for which these concerns do not apply).
引用
- Runge VM. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan). Invest Radiol. 2018. PMID: 30130320. doi:10.1097/RLI.0000000000000507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。